Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.
Miolo G, Muraro E, Martorelli D, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Viel E, Comaro E, Talamini R, Bidoli E, Turchet E, Crivellari D, Dolcetti R.
Miolo G, et al. Among authors: muraro e.
BMC Cancer. 2014 Dec 15;14:954. doi: 10.1186/1471-2407-14-954.
BMC Cancer. 2014.
PMID: 25512030
Free PMC article.
Clinical Trial.